Nicholas Rudy

Business Development Manager responsible for evolving and coordinating strategies within a team of seven OR and hospital-based Account Managers to achieve sustainable growth of the Prevena incisional negative pressure product line. Focus on establishing protocols with Orthopedic, Vascular, Plastic, Cardiothoracic, and General Surgeons to reduce and minimize the risk of surgical site complications

• Researched and identified opportunities for account growth, account penetration and market expansion
• Negotiated and closed agreements with new clients in assigned territory
• Established relationships with key decision-makers within customer's organization to promote growth and retention

Regional Sales Director responsible for the management of seven Account Executives (Sales Representatives) in the Northeast Region of the United States from Virginia to Maine. Representatives in this Acute Patient Handling Division are responsible for the sale of capital equipment (and corresponding disposable components) to hospitals, including but not limited to ceiling lifts, floor lifts, and air-assisted lateral transfer. Job responsibilities include strategy rollout and execution, recruiting and hiring, performance reviews, weekly/monthly/quarterly/yearly product forecasting, expense approval and budget control, and career development

• 01/2021 - 11/2021: Achieved 116% to quota (#1 region in the country out of 5 regions) vs. a baseline of 66.4% to quota (#5 region in the country out of 5 regions before I was hired)
• The Northeast Region has consistently ranked in the bottom 20% of the division for the past three years. It is now ranked at the top of the division for the first time in over four years

Responsible for the sale of a line of wound care, surgical incision management, and open abdomen medical devices across all medical specialties in hospitals and operating rooms

• FY 2020: Achieved 101.2% to quota, full portfolio
• 2H 2019: Achieved 98.6% to quota (vs. 86.7% baseline)
• Devised and deployed optimized sales management and revenue development strategies, boosting the Orlando, FL territory from a bottom 15% national ranking to a top 15% national ranking over an 18-month time frame. Significant growth was achieved and maintained throughout the COVID-19 pandemic, despite a drastic reduction in elective surgeries and hospital census patient counts in Q2/Q3 2020. Sold approx. $1.2M in capital equipment (VAC Ultas) to Lakeland Regional Hospital in the face of a competitive threat to maintain a full KCI portfolio presence, including the addition of 12 SKUs over 18 months

Responsible for the sale of an entire line of wound care medical devices and advanced wound dressings to Health Care Providers in all post-acute care settings

• FY 2016: Achieved 102% to quota
• FY 2017: Achieved 88% to quota
• FY 2018: Achieving 101% to quota
• Devised and deployed optimized sales management and revenue development strategies, boosting the Scranton, PA territory from a bottom 10% national ranking to a top 15% national ranking over a 24-month time frame

Responsible for the sale of the Wearable Cardiac Defibrillator (LifeVest WCD) to Electrophysiologists, as well as Interventional and General Cardiologists in the acute and post-acute setting, including cardiac catheterization and electrophysiology labs

• FY 2013: Achieved 92% to quota with revenue of $382,889, regionally ranked 38 out of 99
• FY 2014: Achieved 121% to quota with revenue of $1,020,170 (regional ranking unavailable due to layoff before report was finalized)

Responsible for the sale of two alternative methods of contraception (Nuvaring vaginal ring and Implanon/Nexplanon implantable contraceptive device) and the Gardasil cervical cancer vaccine to OB-GYNs, primarily in the post-acute setting

• FY 2012: Achieved 106% to quota, regionally ranked 16 out of 88
• FY 2011: Achieved 108% to quota, regionally ranked 13 out of 85
• FY 2010: Achieved 113.5% to quota, regionally ranked 6 out of 92
• FY 2009: Achieved 100.9% to quota, nationally ranked 56 out of 327
• FY 2008: Achieved 93.8% to quota, nationally ranked 141 out of 308
• FY 2007: Achieved 101.7% to quota, nationally ranked 39 out of 344

Responsible for the sale of an extended-release, class II controlled substance (Avinza) to Pain Management Specialists and Primary Care/Internal Medicine Physicians in the post-acute setting

• 2006: Achieved 103.6% to quota, nationally ranked 51/355
• 2005: Achieved 114.8% to quota, nationally ranked 34/370